CA2010256A1 - Proteine anti-cancereuse - Google Patents

Proteine anti-cancereuse

Info

Publication number
CA2010256A1
CA2010256A1 CA2010256A CA2010256A CA2010256A1 CA 2010256 A1 CA2010256 A1 CA 2010256A1 CA 2010256 A CA2010256 A CA 2010256A CA 2010256 A CA2010256 A CA 2010256A CA 2010256 A1 CA2010256 A1 CA 2010256A1
Authority
CA
Canada
Prior art keywords
modified
recognition protein
cell recognition
cancer agent
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2010256A
Other languages
English (en)
Other versions
CA2010256C (fr
Inventor
Allen I. Oliff
Deborah D. Jones
Gwynneth M. Edwards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2010256A1 publication Critical patent/CA2010256A1/fr
Application granted granted Critical
Publication of CA2010256C publication Critical patent/CA2010256C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002010256A 1989-02-17 1990-02-16 Proteine anti-cancereuse Expired - Fee Related CA2010256C (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31254089A 1989-02-17 1989-02-17
US312,540 1989-02-17
US38909289A 1989-08-03 1989-08-03
US389,092 1989-08-03
US44918789A 1989-12-21 1989-12-21
US449,187 1989-12-21

Publications (2)

Publication Number Publication Date
CA2010256A1 true CA2010256A1 (fr) 1990-08-17
CA2010256C CA2010256C (fr) 2000-07-25

Family

ID=27405603

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002010256A Expired - Fee Related CA2010256C (fr) 1989-02-17 1990-02-16 Proteine anti-cancereuse

Country Status (18)

Country Link
EP (1) EP0383599B1 (fr)
JP (2) JPH07106159B2 (fr)
KR (1) KR0169729B1 (fr)
AT (1) ATE133993T1 (fr)
AU (1) AU617039B2 (fr)
CA (1) CA2010256C (fr)
CY (1) CY1987A (fr)
DE (1) DE69025211T2 (fr)
DK (1) DK0383599T3 (fr)
ES (1) ES2085329T3 (fr)
FI (1) FI102383B (fr)
GR (1) GR3019836T3 (fr)
HK (1) HK15597A (fr)
IE (1) IE71934B1 (fr)
IL (1) IL93425A (fr)
NO (1) NO300595B1 (fr)
NZ (1) NZ232564A (fr)
PT (1) PT93178B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
CA2053911C (fr) * 1989-04-21 1999-11-02 Ira H. Pastan Proteines recombinantes de fusion anticorps-toxine
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
AUPM959894A0 (en) * 1994-11-22 1994-12-15 Crc For Biopharmaceutical Research Pty Ltd Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
WO1998029453A1 (fr) * 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Medicaments diriges vers la membrane cellulaire
JP2001525669A (ja) * 1997-05-12 2001-12-11 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 細胞遊走の阻害のための方法および構築物
GB0008802D0 (en) * 2000-04-10 2000-05-31 Univ London Molecule
AU2005257064B2 (en) 2004-06-28 2012-05-10 Yeda Research And Development Co. Ltd. Chimeric proteins and uses thereof
CN105766069B (zh) 2013-11-20 2019-04-16 株式会社村田制作所 多层布线基板及具备该多层布线基板的探针卡
US20180250360A1 (en) * 2015-10-05 2018-09-06 National Institute Of Advanced Industrial Science And Technology Method for detecting cancer cells, reagent for introducing substance into cancer cells, and composition for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
CA2053911C (fr) * 1989-04-21 1999-11-02 Ira H. Pastan Proteines recombinantes de fusion anticorps-toxine

Also Published As

Publication number Publication date
PT93178A (pt) 1990-08-31
KR900012626A (ko) 1990-09-01
DE69025211T2 (de) 1996-09-19
JP2510846B2 (ja) 1996-06-26
JPH07106159B2 (ja) 1995-11-15
IE71934B1 (en) 1997-03-12
EP0383599A3 (fr) 1991-03-27
IE900587L (en) 1990-08-17
NZ232564A (en) 1992-08-26
IL93425A (en) 1999-08-17
DK0383599T3 (da) 1996-08-05
AU617039B2 (en) 1991-11-14
AU4994690A (en) 1990-08-23
HK15597A (en) 1997-02-14
CY1987A (en) 1997-09-05
DE69025211D1 (de) 1996-03-21
FI102383B1 (fi) 1998-11-30
KR0169729B1 (ko) 1999-01-15
GR3019836T3 (en) 1996-08-31
JPH02276590A (ja) 1990-11-13
FI900783A0 (fi) 1990-02-16
NO900758D0 (no) 1990-02-16
FI102383B (fi) 1998-11-30
ATE133993T1 (de) 1996-02-15
IL93425A0 (en) 1990-11-29
JPH07278200A (ja) 1995-10-24
NO300595B1 (no) 1997-06-23
PT93178B (pt) 1996-04-30
CA2010256C (fr) 2000-07-25
NO900758L (no) 1990-08-20
ES2085329T3 (es) 1996-06-01
EP0383599B1 (fr) 1996-02-07
EP0383599A2 (fr) 1990-08-22

Similar Documents

Publication Publication Date Title
AU543198B2 (en) Hexapeptides
AU642403B2 (en) Method for the use and synthesis of peptides
CA2155185A1 (fr) Reactifs par affinite, totalement synthetiques
EP0157643A3 (fr) Anticorps à l'interleukine-2-humaine induite à l'aide de polypeptides synthetiques
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
AU616156B2 (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
CA2127362A1 (fr) Expression et purification d'un facteur tissulaire soluble recombinant
EP0596459A3 (fr) Procédé pour la purification de protéines recombinantes et utilisation de leurs produits
ATE194169T1 (de) Beta-type ähnlicher transformierender wachstumfaktor
CA2075974A1 (fr) Reactifs d'affinite entierement synthetiques
EP0284587A3 (fr) Antigènes peptides synthétiques pour la détection d'infections de HIV-1
AU4994690A (en) Protein anti-cancer agent
CA2019671A1 (fr) Denaturation oxydative d'analytes proteiniques
CA2177179A1 (fr) Antagonistes de la chaperonine 10
EP0869177A3 (fr) Récepteurs humains du facteur de croissance dérivé des plaquettes du type A et B
EP0122628A3 (fr) Anticorps monoclonaux contre l'interféron immun humain
EP0220063A3 (fr) Anticorps anti-interleukine-1 humaine, méthode pour sa production et son utilisation
ES2109225T3 (es) Anticuerpos, su produccion y uso.
CA2100586A1 (fr) Antigenes peptidiques de htlv-i et de htlv-ii et methodes d'utilisation
CA2242347A1 (fr) Procede d'augmentation ou de reduction de la fertilite par utilisation d'un polypeptide dans la liaison sperme-oeuf
KR900002074A (ko) 감마 아트리알 나트륨 이뇨성 폴리펩티드를 인식하는 단일 클론 항체
EP0351244A3 (fr) Anticorps et méthodes d'immunoessais les utilisant
WO1992001794A3 (fr) Proteines semblables a l'ancrod, leur fabrication et utilisation
Koga et al. Monoclonal antibodies specific for high molecular weight form of human epidermal growth factor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed